Biomarkers are used in single or in combination to identify health or disease of the individual. They are used to measure biological states such as blood pressure, cholesterol level and monitor and forecast health level of the individual. Different varieties of biomarkers are applied currently for various applications. Each biological system consists of its personal biomarkers.
Europe Cancer Biomarker Market Size:
According to latest market research report, The Europe cancer biomarker market was valued at USD 3,076.2 million in 2018 and is expected to grow at a CAGR of 11.42% for the years 2018-2025 to reach USD 6,407.3 million. The technological progress in research and developmental activities has progressed the high growth of the cancer biomarker market in Europe.
Growth Drivers, Challenges, and Opportunities - Europe Cancer Biomarker Market
The foremost driving factors for the biomarkers market in Europe are an increase in the number of low costs for conducting clinical trials in its countries. The performance of biomarkers in the diagnostic process is growing rapidly due to its more accurate results. These biomarkers also have some limitations such as the technical issues related to sample and storage. The experiment cost of biomarkers is large. It includes high expense but relatively low cost and benefit rate.
The European market has a huge opportunity to grow in personalized medication on account of the support generated for the biomarkers test, and the growing number of cancer patients in the region. Moreover, the various market segments and sub-segments with respect to biomarkers are proving to be quite profitable for the market growth during the forecast period. Additionally, the lack of acceptance of the cancer biomarker from the general populace, unfavorable compensation and the shortage of skilled personnel maybe some of the major challenges faced by the market in the region.
Geographical Analysis of Europe Cancer Biomarker Market
Europe cancer biomarker market is witnessing significant growth due to technological developments. It includes the regions of Germany, Spain, United Kingdom, Italy, France and the rest of Europe. The growing number of cancer cases and the encouragement by the government for biomarker research and development are aiding the growth for the European market. Some of the associations supporting the market in Europe are European Association for Cancer Research, German Consortium for Translational Cancer Research and European Society for Breast Cancer Specialist.
Some of the promising companies leading the Europe Cancer Biomarker Market:
- Agendia N.V.
- Becton Dickinson and Company
- Qiagen N.V.
- Diadexus Inc.
- Aureon Biosciences Inc.
- Agilent Technologies Inc.
- Clarient Inc.
- Astellas Pharma Inc.
- Beckman Coulter
- Sanofi
- Bristol-Myers Squibb
- Abbott Laboratories
- Roche Diagnostics Ltd.
- Illumina, Inc.
- Celgene Corporation.
This research report includes following segmentation for the Europe Cancer Biomarker Market size and forecast
Europe Cancer Biomarker Market - By Disease
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Cervical Cancer
- Other Cancers
Europe Cancer Biomarker Market - By Services
- Sample Preparation
- Assay Development
- Biomarkers Validation
- Testing
Europe Cancer Biomarker Market - By Application
- Risk Assessment
- Development of Molecular Diagnostics
- Disease Diagnosis
- Drug Discovery
- Development
- Drug Formulation
Europe Cancer Biomarker Market - By Type
- Protein Biomarkers
- Genetic Biomarkers
- Other Biomarkers
Europe Cancer Biomarker Market - By Profiling Technologies
- Omics Technologies
- Imaging Technologies
- Immunoassays
- Cytogenetics
- Bioinformatics
- IVD Multivariate Index Assays
Europe Cancer Biomarker Market- By Region
- United Kingdom
- Germany
- France
- Italy
- Spain
+1 888 709 8757
Chat With Us